Does Cigna Cover Repatha (Evolocumab)?

What Is Repatha and Why Does Coverage Get Complicated?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab raises the number of functional LDL receptors and lowers circulating LDL-C by an average of 59% when added to statin therapy, as demonstrated in the FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 [1]. The FDA first approved evolocumab in August 2015 for adults with primary hyperlipidemia and then expanded that label in December 2017 to include reducing the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease [2].

Because the drug carries a list price near $580 per month, insurers including Cigna place it on a specialty tier and require prior authorization before they will pay. The clinical need is real. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction states that PCSK9 inhibitors are reasonable to add when LDL-C remains 70 mg/dL or above despite maximally tolerated statin plus ezetimibe in very-high-risk ASCVD patients [3]. Cigna's own medical coverage policy mirrors that threshold, and understanding it precisely is the fastest path to an approved claim.

Dosing approved by the FDA is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly via a special monthly auto-injector [2]. Both regimens achieve equivalent LDL-C lowering. Cigna's pharmacy benefit covers both dose forms, though the monthly 420 mg device is sometimes routed through a specialty pharmacy contracted with the plan.

Cigna Prior Authorization Criteria for Repatha

Cigna requires prior authorization for Repatha on every commercial PPO, HMO, and EPO plan. The four core criteria Cigna's pharmacy benefit managers evaluate are: a qualifying diagnosis, a documented LDL-C lab value, evidence of maximally tolerated lipid-lowering therapy, and prescriber type.

Qualifying diagnosis. Cigna approves Repatha for (a) established ASCVD, meaning documented coronary artery disease, prior MI, prior ischemic stroke, or peripheral arterial disease; (b) heterozygous familial hypercholesterolemia (HeFH) confirmed by genetic testing, a validated clinical scoring tool such as the Dutch Lipid Clinic Network score of 6 or above, or a first-degree relative with documented FH; or (c) homozygous familial hypercholesterolemia (HoFH) [4].

LDL-C threshold. For ASCVD, Cigna generally requires LDL-C of 70 mg/dL or above despite therapy. For HeFH, the threshold is typically LDL-C of 100 mg/dL or above. For HoFH, Cigna may waive the numeric threshold given the severity of disease. These values align with the ACC/AHA guideline thresholds [3].

Step therapy. Cigna requires documented use of a maximally tolerated statin. High-intensity therapy means rosuvastatin 20 to 40 mg daily or atorvastatin 40 to 80 mg daily per ACC/AHA definitions [3]. If a statin is not tolerated, Cigna requires documentation of intolerance to at least two separate statins at any dose. Ezetimibe 10 mg daily must also be trialed and either failed to achieve the LDL-C goal or have a documented intolerance. The requirement to trial ezetimibe before PCSK9 inhibition is consistent with American Association of Clinical Endocrinology guidelines published in 2022 [5].

Prescriber type. Some Cigna plans require that the prescribing physician be a cardiologist, endocrinologist, or lipidologist, though this restriction is less common on large employer self-funded plans. Confirming prescriber requirements before submission avoids a preventable denial [6].

Lab documentation. Two LDL-C measurements at least four weeks apart while on maximally tolerated therapy strengthen the file. A single value is typically accepted, but duplicate labs reduce the chance of a "insufficient documentation" denial [4].

Initial PA approvals are generally granted for 12 months. Renewal requires repeat LDL-C showing continued response to treatment, not an arbitrary number, and ongoing documentation that the original qualifying condition persists.

What Formulary Tier Is Repatha on Cigna?

Repatha sits on Cigna's specialty drug tier across most commercial formularies, typically Tier 4 or Tier 5 depending on the specific plan design. Specialty tier cost-sharing commonly ranges from 25% to 33% coinsurance or a fixed copay of $100, $200 per fill after the deductible is met. On high-deductible health plans (HDHPs), the full list price applies until the deductible is satisfied.

Cigna's standard commercial formulary does not list evolocumab as a preferred specialty agent, which means the plan will not automatically substitute it for a non-preferred designation without a PA showing clinical necessity. The competing PCSK9 inhibitor alirocumab (Praluent) occupies a similar tier. Cigna's formulary position differs by contract year and by whether the employer plan is fully insured or self-funded, so checking the Summary of Benefits and Coverage (SBC) for the specific plan year is the only reliable method to confirm current tier and cost-sharing [7].

The FDA's Orange Book confirms evolocumab has no currently approved generic or biosimilar in the United States as of mid-2025, which is why list prices remain high and insurer management remains tight [8].

Step Therapy Requirements: What You Have to Try First

Cigna's step therapy protocol for Repatha is sequential, and failing to document each step in the medical record is the most common reason for initial denial. The required sequence is:

1. High-intensity statin therapy at maximally tolerated dose for at least 8 to 12 weeks.
2. Addition of ezetimibe 10 mg daily for at least 4 to 8 weeks on top of the statin.
3. Repeat fasting LDL-C lab confirming failure to reach goal or documented adverse effect requiring discontinuation.

Each step must be documented in office notes, not just in a pharmacy fill history. A 2021 analysis published in JAMA Cardiology found that among ASCVD patients who qualified for PCSK9 inhibitor therapy by guideline criteria, only 55% had ezetimibe documented in the chart before the PCSK9 inhibitor was prescribed, creating easy denial grounds for insurers [9]. Proactive documentation closes that gap.

For patients with HoFH, Cigna typically waives the full statin-plus-ezetimibe step therapy because LDL receptor defects prevent meaningful response to those agents. The FDA label for evolocumab specifically addresses HoFH dosing at 420 mg monthly, with the option to increase to 420 mg every two weeks if response is insufficient at 12 weeks [2].

Patients with statin myopathy documented by creatine kinase elevation above 10 times the upper limit of normal, or with myalgia that resolves with discontinuation and recurs with rechallenge, qualify for a statin-intolerance exception. Two separate statin trials are required for that exception. Clinicians should include the specific statin names, doses, duration, and symptom description in the PA request letter.

How to Appeal a Cigna Denial of Repatha

Cigna's denial rate for PCSK9 inhibitors on first submission is not published, but a 2022 report from the Kaiser Family Foundation found that specialty drug PA requests across large commercial insurers are denied at rates between 10% and 20% on initial submission, with appeal success rates of 39 to 59% [10]. Appealing is worth doing.

Level 1 internal appeal. File within 180 days of the denial notice. Submit a physician letter addressing each denial reason specifically. If Cigna denied on grounds of "failure to meet step therapy," the letter must provide dates, doses, and duration of each prior therapy plus labs. Attach office notes, not just the pharmacy print-out. Cigna must respond to a standard appeal within 30 days; urgent appeals must be answered within 72 hours under federal rules for plans subject to the Employee Retirement Income Security Act (ERISA) [11].

Level 2 internal appeal. If Level 1 fails, request a second-level review by a Cigna medical director. This is the point at which a peer-to-peer call between the prescribing cardiologist or endocrinologist and the Cigna medical director can shift the outcome. Peer-to-peer calls succeed because they allow the treating physician to present clinical nuance that written documentation alone may not convey [6].

External independent review organization (IRO). After exhausting internal appeals, Cigna enrollees in fully insured state-regulated plans can request external review by a state-approved IRO. ERISA self-funded plan members may request external review under the Affordable Care Act's federal external review process [11]. External reviewers overturn internal denials approximately 40% of the time for specialty biologics, based on data compiled from state insurance department reports [10].

Expedited appeal. If the patient is hospitalized or at imminent cardiovascular risk, request an expedited appeal. Cigna must respond within 72 hours. Include a brief physician attestation explaining why delay poses a clinical risk.

Key documents to include in any appeal:

• Two fasting LDL-C labs on maximally tolerated therapy, with dates
• Office notes documenting statin trial(s) with dose and duration
• Office notes documenting ezetimibe trial with dose and duration
• Diagnosis documentation: cath report for CAD, imaging for stroke, genetic report for FH
• Peer-reviewed literature: the FOURIER trial showed a 15% relative risk reduction in the primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina) over a median of 2.2 years (P<0.001) [1]
• ACC/AHA guideline language directly stating that PCSK9 inhibitors are a Class IIa recommendation for very-high-risk ASCVD patients with LDL-C remaining 70 mg/dL or above [3]

The framework above represents the HealthRX Repatha Appeal Ladder: a sequenced checklist used by the HealthRX clinical team when assisting patients through Cigna PA and appeal workflows. Clinicians can request the printable PDF version through the HealthRX provider portal.

The Manufacturer Savings Card and Patient Assistance Program

Amgen, the manufacturer of Repatha, offers a copay assistance program called the Repatha SupportPlus program. Eligible commercially insured patients may pay as little as $5 per month after the card is applied, up to a maximum benefit amount [12]. The card cannot be used by patients enrolled in Medicare Part D, Medicaid, or any other government-funded health program. Patients with Cigna commercial employer coverage are generally eligible.

For uninsured patients or those whose income qualifies, Amgen's patient assistance program provides Repatha at no cost. Income eligibility is generally set at or below 600% of the federal poverty level [12]. Applying takes approximately 2 to 3 weeks, which means the application should be submitted before or during the PA appeal, not after.

The savings card does not substitute for insurance coverage and does not count toward deductible accumulation on plans that exclude manufacturer coupons from deductible calculations, a provision that became more common after a 2021 IRS notice [13]. Patients should verify with Cigna whether copay card payments count toward their out-of-pocket maximum before relying on the card as a long-term cost strategy.

Clinical Evidence Supporting Coverage Decisions

Cigna's coverage policy is grounded in the same clinical evidence that informs ACC/AHA guidelines. The FOURIER trial enrolled 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or above on optimized statin therapy. Evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by a mean of 59% from baseline (from approximately 92 mg/dL to 30 mg/dL) and reduced the composite primary endpoint by a hazard ratio of 0.85 (95% CI 0.79, 0.92, P<0.001) over 2.2 years [1].

The GLAGOV trial (N=968) used intravascular ultrasound and found that evolocumab added to statin therapy produced regression of coronary atherosclerosis at 76 weeks, with a mean percent atheroma volume change of -0.95% vs. +0.05% for placebo (P<0.001) [14]. This mechanistic evidence supports the claim that LDL-C reduction below 70 mg/dL translates into plaque regression, not just endpoint prevention.

For HoFH specifically, a 12-week randomized trial (N=49) showed that evolocumab 420 mg monthly reduced LDL-C by 30.9% from baseline in patients with receptor-negative mutations and by 41.5% in patients with receptor-defective mutations, with both reductions reaching statistical significance compared to placebo [15]. The FDA label reflects these data and formed the basis for the HoFH indication approved in 2015 [2].

The AACE 2022 Dyslipidemia Guidelines recommend PCSK9 inhibitor therapy for very-high-risk patients with LDL-C above 55 mg/dL who have already been on maximally tolerated statin plus ezetimibe therapy, a threshold even lower than Cigna's PA cutoff of 70 mg/dL [5]. When the treating physician cites this guideline and the patient's LDL-C remains above 55 mg/dL, the discrepancy between Cigna's threshold and the professional society recommendation strengthens an appeal letter.

The National Lipid Association's consensus statement published in the Journal of Clinical Lipidology notes that cost barriers to PCSK9 inhibitor access have resulted in underutilization of evidence-based therapy in the highest-risk patients, with some estimates suggesting fewer than 20% of guideline-eligible patients in the United States receive a PCSK9 inhibitor [16].

What to Do If Cigna Denies After All Appeals

State insurance commissioners and the Centers for Medicare and Medicaid Services maintain grievance pathways separate from the insurer's internal appeal process. Filing a complaint with the state insurance commissioner does not require an attorney and can prompt expedited review of the denial [11]. Some states have explicit step-therapy override laws: as of 2024, more than 30 states have enacted step-therapy exception statutes requiring insurers to grant overrides within defined timeframes when a prescribing physician documents clinical need [17].

The No Surprises Act and related federal transparency rules require insurers to provide denial notices that specify the exact clinical criteria not met, giving physicians a precise target for the appeal letter [11]. If Cigna's denial letter does not specify the clinical criterion that was unmet, that omission is itself grounds for a complaint to the state insurance commissioner or the U.S. Department of Labor for ERISA plans.

Switching to a plan year with a different formulary is a legitimate option for patients in open enrollment. Checking whether Cigna's next plan year or a competing carrier's formulary offers preferred-tier placement for evolocumab may reduce cost-sharing more reliably than repeated appeals. The Medicare Part D formulary finder at CMS.gov and the employer benefits portal are the right tools for this comparison [7].

Does Cigna Cover Repatha for Weight Loss?

No. Evolocumab has no FDA approval for weight loss and no published evidence of meaningful adipose reduction. Cigna will not approve Repatha for any weight-related indication, and submitting a PA request citing weight loss as the clinical rationale will result in an automatic denial. Patients interested in weight management should discuss GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) with their clinician, as that drug carries an FDA approval specifically for chronic weight management in adults with BMI 30 kg/m2 or above, or BMI 27 kg/m2 or above with a weight-related comorbidity [18].